Return to homepagePandemic Pact

DEFIBROTIDE AS PREVENTION AND TREATMENT OF COVID-19 RESPIRATORY DISTRESS AND CYTOKINE RELEASE SYNDROME

  • Funded by National Institute of Health Carlos III [El Instituto de Salud Carlos III] (ISCIII)
  • Total publications:0 publications

Grant number: COV20_00399

Grant search

Key facts

  • Disease

    COVID-19

  • Funder

    National Institute of Health Carlos III [El Instituto de Salud Carlos III] (ISCIII)

  • Principal Investigator

    Jose M Moraleda Jiménez

  • Research Location

    Spain

  • Lead Research Institution

    FUNDACION PARA LA FORMACION E INVESTIGACION SANITARIAS DE LA REGION DE MURCIA (FFIS)

  • Research Priority Alignment

    N/A

  • Research Category

    Therapeutics research, development and implementation

  • Research Subcategory

    Prophylactic use of treatments

  • Special Interest Tags

    N/A

  • Study Type

    Clinical

  • Clinical Trial Details

    Randomized Controlled Trial

  • Broad Policy Alignment

    Pending

  • Age Group

    Adults (18 and older)

  • Vulnerable Population

    Unspecified

  • Occupations of Interest

    Unspecified

Abstract

This project aims to demonstrate that DEF is effective and safe as a therapy for COVID-19. The goal is to decrease mortality by a rate of at least 25%. 120 patients with WHO COVID-19 grades 4, 5 and 6 will be included, who will be randomized 2: 1 to receive the experimental or control treatment respectively, and will be stratified according to the WHO classification into two groups: 40 patients WHO grade 4-5 will receive experimental treatment + standard treatment and 20 patients (control group) will receive placebo plus standard treatment, and 40 WHO grade 6 patients will receive experimental treatment + standard treatment, and 20 patients (control group) they will receive placebo plus standard treatment.